Soligenix Inc. announced that the Data Monitoring Committee has recommended stopping the Phase 3 FLASH 2 trial of its photodynamic therapy HyBryte for cutaneous T‑cell lymphoma (CTCL) due to futility. The decision follows an interim analysis that showed no statistically significant reduction in CTCL lesions after 18 weeks of treatment, a result that contrasts with the positive signal observed in the earlier Phase 3 FLASH study.
The interim data revealed that, unlike the first FLASH study where a 49% response rate was achieved after 18 weeks, the second study failed to demonstrate a similar benefit. The lack of efficacy in the larger, longer‑duration trial suggests that the therapeutic effect observed earlier may not be reproducible at the scale required for regulatory approval.
Financially, Soligenix reported a net loss of $11.1 million for the year ended December 31, 2025, up from a $8.3 million loss in 2024, and zero revenue in 2025 compared with $0.1 million in 2024. Cash on hand was $5.9 million as of April 28, 2026. The CTCL market is sizable, with a 7‑market‑segment valuation of approximately $1.042 billion in 2025, projected to reach $1.622 billion by 2034, and a global market estimate of $3.26 billion in 2023, expected to grow to $4.53 billion by 2030.
"We are obviously very disappointed with the unanticipated outcome of the study," said Christopher J. Schaber, PhD, President and CEO. "Despite the fact that HyBryte™ demonstrated statistically significant reductions in CTCL lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study." He added that the company would analyze the data further to determine why the study did not meet expectations and to identify any patient subgroups that might still benefit. He also noted that with approximately $5.9 million of cash, Soligenix will evaluate all strategic options, including merger and acquisition opportunities and the potential of advancing its dusquetide program for Behçet’s disease.
The halt of the FLASH 2 trial removes a critical regulatory milestone for HyBryte, jeopardizing the company’s ability to secure FDA approval and threatening its capacity to attract future funding or partnerships. With limited cash reserves and a net loss trajectory, Soligenix is now focused on diversifying its pipeline, particularly the dusquetide program, and exploring strategic alternatives to maintain its going‑concern status.
Investors reacted negatively, citing concerns about the company’s cash position, the impact on its ability to secure future capital, and the broader implications for its flagship product’s regulatory pathway.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.